- Company
- Yuhan Corporation records new quarterly sales
- by Chon, Seung-Hyun Aug 1, 2022 09:14pm
- Yuhan set a new quarterly sales record. In the domestic market, both Rx and OTC drugs were strong, and overseas businesses were also doing well. Operating profit fell due to a decrease in technology fee revenue and an increase in R&D investment. Yuhan Corporation announced on the 28th that its operating profit based on separate financial stateme
- Company
- OAD drug Betmiga’s price halved with the entry of generics
- by Kim, Jin-Gu Jul 29, 2022 05:51am
- Prescription sales of Astella’s overactive bladder (OAD) treatment ‘Betmiga (mirabegron)’ halved in just one year. The analysis is that Betmiga’s sales took a direct blow from the launch of generics and the drug price cut that followed. Its generics, which had been released after Q2 in 2020, have been gradually increasing their influence
- Company
- Ildong Pharmaceutical operates about 20 R&D pipelines
- by Chon, Seung-Hyun Jul 29, 2022 05:51am
- Ildong Pharmaceutical is using an aggressive new drug development strategy, risking a deficit for seven consecutive quarters. Ildong Pharmaceutical is operating about 20 new drug pipelines, and five of them have entered the clinical stage. It is focusing on enhancing the performance and possibility of new drugs by establishing a cooperation syst
- Company
- Tax credit when acquiring an overseas vaccine company
- by Kim, Jin-Gu Jul 29, 2022 05:50am
- Starting next year, domestic companies that buy overseas vaccine technology companies are expected to be able to expect corporate tax deductions of up to 10% of the acquisition price. According to the pharmaceutical industry on the 27th, the Ministry of Strategy and Finance recently finalized and announced the "2022 Tax Reform Plan." The g
- Company
- 13 companies overcome key patents for Entresto
- by Kim, Jin-Gu Jul 29, 2022 05:50am
- Domestic pharmaceutical companies won the first trial of the patent dispute over Novartis' Entresto (Valsartan + Sacubitril). it is predicted that domestic pharmaceutical companies will soon launch generics for Entresto as they succeeded in targeting use patents that were considered key patents among Entresto patents. ◆ 13 domestic pharma
- Company
- Sanofi to increase supply volume of its flu vaccines in KOR
- by Jul 28, 2022 05:54am
- The competition in the flu (influenza) vaccine market is expected to intensify this year. With Sanofi succeeding in making the government bid at a cheaper price and expected to bring more supply into the private market, larger-than-expected quantities of the flu vaccine are expected to be released into the private market. According to ind
- Company
- Samsung Biologics's 1H sales exceed ₩1 trillion...
- by Kim, Jin-Gu Jul 28, 2022 05:54am
- Samsung Biologics 1H sales exceeded &8361;1 trillion for the first time since its establishment. The company attributed its improved results to the rapid growth of its CMO business, the increased capacity utilization rate of its 3rd plant, and the increased exchange rate. ◆"Lands 7 contracts in 1H… the company’s 1st, 2nd, and
- Company
- 5-year PDRN dispute comes to an end... PharmaResearch wins
- by Kim, Jin-Gu Jul 27, 2022 05:49am
- The long patent dispute between PharmaResearch and BMI Korea over the PDRN manufacturing method has finally come to an end, with the court ruling in favor of the original company, PharmaResearch. The industry expects the trial win to bring momentum to the rise of PDRN-based pharmaceuticals and devices, such as ‘Rejuran’ and ‘Conjuran.
- Company
- One-shot treatment Zolgensma lands in GHs with reimb
- by Eo, Yun-Ho Jul 26, 2022 06:05am
- The ‘one-shot’ treatment Zolgensma may be prescribed with reimbursement at general hospitals in Korea. According to industry sources, Novartis Korea’s spinal muscular atrophy (SMA) treatment Zolgensma (onasemnogene abeparvovec) passed the drug committees of the Big 5 tertiary hospitals in Korea including the Samsung Medical Center
- Company
- Daewoong to expand its diagnostic kit business globally
- by Nho, Byung Chul Jul 26, 2022 06:05am
- The number of new COVID-19 confirmed patients is increasing rapidly again. As of May this year, the number of confirmed patients in Korea has continued to decline, but it has rebounded since the record of 3,423 confirmed patients at the end of June, and the doubling of confirmed patients has continued for four weeks. In addition, face-to-face
